Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare.

IF 17 1区 哲学 Q1 ETHICS
American Journal of Bioethics Pub Date : 2025-06-01 Epub Date: 2025-02-23 DOI:10.1080/15265161.2025.2457713
Megan A Allyse, Preya Agam, Yvonne Bombard, Roel Feys, McKenna Horstmann, Assata Kokayi, Rosario Isasi, Karen M Meagher, Marsha Michie, Kiran Musunuru, Kelly E Ormond, Kirsten A Riggan, Jane Q Yap
{"title":"Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare.","authors":"Megan A Allyse, Preya Agam, Yvonne Bombard, Roel Feys, McKenna Horstmann, Assata Kokayi, Rosario Isasi, Karen M Meagher, Marsha Michie, Kiran Musunuru, Kelly E Ormond, Kirsten A Riggan, Jane Q Yap","doi":"10.1080/15265161.2025.2457713","DOIUrl":null,"url":null,"abstract":"<p><p>Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.</p>","PeriodicalId":50962,"journal":{"name":"American Journal of Bioethics","volume":" ","pages":"11-25"},"PeriodicalIF":17.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Bioethics","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1080/15265161.2025.2457713","RegionNum":1,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0

Abstract

Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.

建设更好的医学:转化正义和追求公平的美国医疗保健。
尽管有相当大的科学进步和监管途径的演变,以确保安全性和有效性,美国医疗保健继续看到越来越大的健康差距。这表明,临床翻译本身不能成为衡量其自身成功的唯一标准,特别是当最边缘化的患者在医疗创新的发展和实施中被忽视时。这就提出了一个问题,即一个狭隘地关注技术成就的系统能否履行医学和公共卫生的道德义务。我们认为,传统的技术官僚标准未能将规范性考虑纳入生物医学翻译。我们需要的是一个超越安全性和有效性的转化领域,以预测所提出的技术如何在现有的社会中发挥作用。我们提出了另一个衡量成功的标准:翻译公正。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Bioethics
American Journal of Bioethics 社会科学-科学史与科学哲学
CiteScore
12.30
自引率
26.90%
发文量
250
审稿时长
6-12 weeks
期刊介绍: The American Journal of Bioethics (AJOB) is a renowned global publication focused on bioethics. It tackles pressing ethical challenges in the realm of health sciences. With a commitment to the original vision of bioethics, AJOB explores the social consequences of advancements in biomedicine. It sparks meaningful discussions that have proved invaluable to a wide range of professionals, including judges, senators, journalists, scholars, and educators. AJOB covers various areas of interest, such as the ethical implications of clinical research, ensuring access to healthcare services, and the responsible handling of medical records and data. The journal welcomes contributions in the form of target articles presenting original research, open peer commentaries facilitating a dialogue, book reviews, and responses to open peer commentaries. By presenting insightful and authoritative content, AJOB continues to shape the field of bioethics and engage diverse stakeholders in crucial conversations about the intersection of medicine, ethics, and society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信